about
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabMylip makes an Idol turn into regulation of LDL receptorInfluence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese peopleChronic alcohol consumption disrupted cholesterol homeostasis in rats: down-regulation of low-density lipoprotein receptor and enhancement of cholesterol biosynthesis pathway in the liverLipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes.Inflammation stimulates the expression of PCSK9Proprotein convertase subtilisin/kexin type 4 in mammalian fertility: a review.PCSK9: an emerging target for treatment of hypercholesterolemia.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.Actinidia chinensis Planch root extract inhibits cholesterol metabolism in hepatocellular carcinoma through upregulation of PCSK9.Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).SILAC-based quantitative proteomic analysis of gastric cancer secretome.Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor.PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans.Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum.Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
P2860
Q26747776-3158F206-B473-4595-A3A9-52631E6052EEQ28255464-9BF8971B-F22A-44FF-BB06-141574FDDF18Q35014317-1F5AEB32-F448-47CB-A249-C83C011C3D5DQ35096270-8E148CD3-619B-40BA-937F-5E6C3EF23B95Q35436046-0F15DBD2-5F04-4FBB-AA79-C0BFFA543C4FQ35677146-2F3F4BE0-3227-4B48-AEE6-3E3DE94EA010Q35847854-9BA79236-FF47-41BD-95F3-6BE7EA111133Q36945328-BE7169F9-5C78-454F-80D9-0B97CE761C02Q37358452-9D076084-D95D-4C7B-97BD-D842CFFC7C6EQ37825903-B77B0DEF-8F56-4B9A-BE04-7ED2E5DABF56Q38109960-6CA323B0-C40B-4227-B398-93AB31AE0970Q38971642-993F34C0-195D-465E-9B58-7312615CB55AQ39175455-972098EE-3D29-42D2-92C1-229DA565C676Q39242942-59E02155-B3EA-4B5F-9AEE-F0471FAA57DDQ39887053-B494B0F2-71E8-42C7-985A-92E9FBF7F081Q39979455-DE92E33D-3B03-4D9B-AD08-287B9653B371Q42545755-D2352B27-5E5B-45CF-BEBF-F169E5E2EA7BQ49898645-1AB5CC55-7BF8-40A2-9A51-87F2FDB9B199Q51305608-A84C485D-AA13-4CEA-AE99-4E12C3B23EADQ58258510-2A0D01AF-BC80-47F8-B28D-158669DAB00E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PCSK9: an enigmatic protease.
@en
PCSK9: an enigmatic protease.
@nl
type
label
PCSK9: an enigmatic protease.
@en
PCSK9: an enigmatic protease.
@nl
prefLabel
PCSK9: an enigmatic protease.
@en
PCSK9: an enigmatic protease.
@nl
P1476
PCSK9: an enigmatic protease
@en
P2093
Dayami Lopez
P304
P356
10.1016/J.BBALIP.2008.01.003
P407
P50
P577
2008-02-02T00:00:00Z